We are live on ! Find out more
TGTX icon

TG Therapeutics
TGTX

46 hedge funds and large institutions have $33.6M invested in TG Therapeutics in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 6

188% more capital invested

Capital invested by funds: $11.7M → $33.6M (+$21.9M)

143% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 7

28% more funds holding

Funds holding: 36 → 46 (+10)

Holders
46
Holders Change
+10
Holders Change %
+27.78%
% of All Funds
1.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
18
Reduced
6
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BM
Bridger Management
New York
+$9.17M
2
Jennison Associates
Jennison Associates
New York
+$5.33M
3
BBA
Baker Bros. Advisors
New York
+$3.67M
4
RCM
RA Capital Management
Massachusetts
+$3.67M
5
SM
Sabby Management
Florida
+$1.68M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$724K
2
Morgan Stanley
Morgan Stanley
New York
-$211K
3
Jane Street
Jane Street
New York
-$155K
4
NI
Numeric Investors
Massachusetts
-$122K
5
Bank of America
Bank of America
North Carolina
-$97.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$92K +$66.7K +10,902 +143%
LOM
27
Loeb Offshore Management
New York
$82K +$99.3K +16,242 New
ARTA
28
A.R.T. Advisors
New York
$71K +$87.3K +14,268 New
NFA
29
Nationwide Fund Advisors
Ohio
$62K +$50K +8,173 +202%
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$59K +$2.3K +376 +3%
BRWA
31
B. Riley Wealth Advisors
Florida
$56K – – –
AQR Capital Management
32
AQR Capital Management
Connecticut
$52K +$62.4K +10,200 New
AIG
33
American International Group
New York
$43.6K +$52.4K +8,563 New
RFC
34
Russell Frank Company
Washington
$42K +$416 +68 +1%
Bank of America
35
Bank of America
North Carolina
$40K -$97.9K -16,008 -67%
BA
36
BlackRock Advisors
Delaware
$36K +$8.91K +1,457 +26%
SO
37
STRS Ohio
Ohio
$30K – – –
AllianceBernstein
38
AllianceBernstein
Tennessee
$15K -$7.75K -1,267 -31%
TRCT
39
Tower Research Capital (TRC)
New York
$15K +$18.2K +2,977 +4,962%
U
40
UBS
Switzerland
$12K +$15K +2,450 New
Ameriprise
41
Ameriprise
Minnesota
$5K +$1.05K +171 +21%
Barclays
42
Barclays
United Kingdom
$3K -$544 -89 -13%
Citigroup
43
Citigroup
New York
$3K -$520 -85 -12%
Janus Henderson Group
44
Janus Henderson Group
United Kingdom
$2K – – –
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
$2K +$1.96K +320 New
Goldman Sachs
46
Goldman Sachs
New York
– -$724K -113,299 Closed
Morgan Stanley
47
Morgan Stanley
New York
– -$211K -32,980 Closed
Jane Street
48
Jane Street
New York
– -$155K -24,227 Closed
NI
49
Numeric Investors
Massachusetts
– -$122K -19,100 Closed
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
– -$79K -12,407 Closed
1
2
3

TGTX Hedge Fund Activity: Q3 2013 in Review

46 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2013, worth a combined $33.6M — up 188% from $11.7M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new TGTX positions and 7 closed out — a net gain of 10 holders — while 18 added to existing stakes and 6 trimmed.

The largest buyer was Bridger Management, opening a new position worth an estimated $9.17M. The largest seller was Goldman Sachs, exiting entirely with an estimated $724K sold.

  • 46 institutional investors held TG Therapeutics (TGTX) as of Q3 2013, up from 36 in Q2 2013.
  • Funds reported $33.6M of TG Therapeutics stock for Q3 2013, up 188% quarter-over-quarter.
  • 17 funds opened new TG Therapeutics positions in Q3 2013 and 7 closed out, a net change of +10 holders.
  • The largest TG Therapeutics buyer in Q3 2013 was Bridger Management, an estimated $9.17M added.
  • The largest TG Therapeutics seller in Q3 2013 was Goldman Sachs, an estimated $724K sold.

Based on aggregated 13F filings for Q3 2013.